share_log

Johnson & Johnson | 10-Q: Q2 2024 Earnings Report

Johnson & Johnson | 10-Q: Q2 2024 Earnings Report

強生 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/26 04:04

Moomoo AI 已提取核心訊息

Johnson & Johnson reported Q2 2024 worldwide sales of $22.4 billion, representing a 4.3% increase year-over-year, with operational growth of 6.6% offset by a negative currency impact of 2.3%. The Innovative Medicine segment grew 5.5% to $14.5 billion, driven by strong performance of key brands including DARZALEX, TREMFYA and ERLEADA. MedTech segment sales increased 2.2% to $8.0 billion.The company's earnings before tax decreased to $5.7 billion from $6.3 billion in Q2 2023, with margin declining to 25.6% from 29.3%. This was primarily impacted by acquisition and integration costs related to the $13.1 billion Shockwave Medical acquisition completed in May 2024, as well as a $0.4 billion loss from the Kenvue share exchange transaction.Looking ahead, J&J is pursuing multiple pathways to resolve talc claims, including a proposed $6.5 billion settlement plan. The company maintained strong liquidity with $24.9 billion in cash and equivalents at quarter-end. Management continues to invest in growth initiatives while advancing its pharmaceutical and medical device portfolios through strategic acquisitions and R&D investments.
Johnson & Johnson reported Q2 2024 worldwide sales of $22.4 billion, representing a 4.3% increase year-over-year, with operational growth of 6.6% offset by a negative currency impact of 2.3%. The Innovative Medicine segment grew 5.5% to $14.5 billion, driven by strong performance of key brands including DARZALEX, TREMFYA and ERLEADA. MedTech segment sales increased 2.2% to $8.0 billion.The company's earnings before tax decreased to $5.7 billion from $6.3 billion in Q2 2023, with margin declining to 25.6% from 29.3%. This was primarily impacted by acquisition and integration costs related to the $13.1 billion Shockwave Medical acquisition completed in May 2024, as well as a $0.4 billion loss from the Kenvue share exchange transaction.Looking ahead, J&J is pursuing multiple pathways to resolve talc claims, including a proposed $6.5 billion settlement plan. The company maintained strong liquidity with $24.9 billion in cash and equivalents at quarter-end. Management continues to invest in growth initiatives while advancing its pharmaceutical and medical device portfolios through strategic acquisitions and R&D investments.
強生報告2024年第二季度全球銷售額爲224億美金，同比增長4.3%，其中運營增長爲6.6%，但受到2.3%的負貨幣影響。創新藥物部門增長5.5%至145億美金，主要受到DARZALEX、TREMFYA和ERLEADA等主要品牌表現強勁的推動。醫療技術部門銷售額增長2.2%至80億美金。公司的稅前盈餘從2023年第二季度的63億美金下降至57億美金，利潤率從29.3%下降至25.6%。這主要受到與2024年5月完成的131億美金ShockWave Medical收購相關的收購和整合成本的影響，以及Kenvue股份交易造成的4億美金損失。展望未來，強生正在尋求多種途徑解決滑石粉索賠問題，包括提議的65億美金和解計劃。公司在季度末保持強勁的流動性，現金及現金等價物達249億美金。管理層繼續投資於增長計劃，同時通過戰略收購和研發投資推動其藥品和器械組合的發展。
強生報告2024年第二季度全球銷售額爲224億美金，同比增長4.3%，其中運營增長爲6.6%，但受到2.3%的負貨幣影響。創新藥物部門增長5.5%至145億美金，主要受到DARZALEX、TREMFYA和ERLEADA等主要品牌表現強勁的推動。醫療技術部門銷售額增長2.2%至80億美金。公司的稅前盈餘從2023年第二季度的63億美金下降至57億美金，利潤率從29.3%下降至25.6%。這主要受到與2024年5月完成的131億美金ShockWave Medical收購相關的收購和整合成本的影響，以及Kenvue股份交易造成的4億美金損失。展望未來，強生正在尋求多種途徑解決滑石粉索賠問題，包括提議的65億美金和解計劃。公司在季度末保持強勁的流動性，現金及現金等價物達249億美金。管理層繼續投資於增長計劃，同時通過戰略收購和研發投資推動其藥品和器械組合的發展。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    施貴寶
    BMY
    -- 60.020
    默沙東
    MRK
    -- 89.230
    賽諾菲安萬特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯維公司
    ABBV
    -- 205.290
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點